Anzeige
Mehr »
Login
Donnerstag, 28.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QFAT | ISIN: US36322Q1076 | Ticker-Symbol:
NASDAQ
28.03.24
16:16 Uhr
0,795 US-Dollar
+0,005
+0,63 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GALECTO INC Chart 1 Jahr
5-Tage-Chart
GALECTO INC 5-Tage-Chart

Aktuelle News zur GALECTO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiGalecto, Inc. - 8-K, Current Report2
12.03.Galecto Inc reports results for the quarter ended in December - Earnings Summary2
08.03.Galecto, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
08.03.Galecto, Inc. - 10-K, Annual Report3
22.01.GB-2064 by Galecto for Post-Polycythemia Vera Myelofibrosis (PPV-MF): Likelihood of Approval2
22.01.GB-2064 by Galecto for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF): Likelihood of Approval3
22.12.23Galecto posts myelofibrosis data as search for savior continues, investors shrug1
21.12.23Galecto stock rallies 25% on positive data for myelofibrosis drug3
21.12.23Galecto, Inc. - 8-K, Current Report2
21.12.23Galecto, Inc.: Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis299BOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
► Artikel lesen
07.11.23Galecto Inc reports results for the quarter ended in September - Earnings Summary1
06.11.23Galecto, Inc. - 10-Q, Quarterly Report3
23.10.23Galecto, Inc. - 8-K, Current Report1
02.10.23Galecto, Inc. - 8-K, Current Report1
26.09.23Galecto, Inc.: Galecto Announces Plans to Explore Strategic Alternatives391BOSTON, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced...
► Artikel lesen
15.08.23Galecto, Inc.: Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis238BOSTON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments...
► Artikel lesen
31.07.23Galecto, Inc.: Galecto Reports Second Quarter Operating and Financial Results349BOSTON, July 31, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
► Artikel lesen
28.04.23Galecto, Inc.: Galecto Reports First Quarter Operating and Financial Results385 BOSTON, April 28, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for...
► Artikel lesen
18 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1